ArticleAME case reports2025
Chronic myeloid leukemia in a patient treated with palbociclib and exemestane: a case report.
Article in AME case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer is the most common type of cancer among women worldwide. Hormone receptor-positive (HR Case Description: In this study, we present a case of a 71-year-old woman who was diagnosed with metastatic breast cancer and subsequently developed chronic myeloid leukemia (CML) following her treatment regimen with palbociclib and exemestane. In response to this new diagnosis, the patient commenced therapy with imatinib mesylate while discontinuing palbociclib and receiving exemestane alone for breast cancer. After three months of diligent therapy with imatinib, chronic myeloid leukemia was effectively managed, which permitted the reintroduction of palbociclib at a reduced dosage. Conclusions: This case underscores the pressing need for further research to enhance our understanding of the adverse events associated with treatment using CDK4/6 inhibitors, particularly concerning their effects on the hematological system. Additionally, it highlights the significance of long-term monitoring in clinical practice for patients receiving therapy with CDK4/6 inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.